ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma

BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

(2010) Hyun Jeong Shim et al.   CANCER SCIENCE

Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity

(2010) Frédéric Chibon et al.   NATURE MEDICINE

Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis

(2010) Mary Ellen Moynahan et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series

(2009) F. Grosso et al.   ANNALS OF ONCOLOGY

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

(2009) C. Forni et al.   MOLECULAR CANCER THERAPEUTICS

BRCA1 and its toolbox for the maintenance of genome integrity

(2009) Michael S.Y. Huen et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

DNA Damage, Aging, and Cancer

(2009) Jan H.J. Hoeijmakers   NEW ENGLAND JOURNAL OF MEDICINE

Effect ofBRCA1Haplotype on Survival of Non–Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

(2008) Hong-Tae Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature

(2008) Adam Vilmar et al.   LUNG CANCER

Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers

(2008) E. V. Stevens et al.   MOLECULAR CANCER THERAPEUTICS